RECRUITING

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

Description

This phase II trial test tests how well repurposing atovaquone works in treating patients with platinum-resistant ovarian cancer. Atovaquone is used for the treatment or prevention of certain infections. Atovaquone is in a class of medications called antiprotozoal agents. It works by stopping the growth of certain types of protozoa that can cause pneumonia. Giving atovaquone may be effective in treating platinum-resistant ovarian cancer and result in improved outcomes compared to standard chemotherapy regimens.

Conditions

Ovarian High Grade Serous AdenocarcinomaPlatinum-Resistant Ovarian Carcinoma
Talk to us

Related Conditions:

Ovarian High Grade Serous AdenocarcinomaPlatinum-Resistant Ovarian Carcinoma

Study Overview

On this page

Study Details

Study overview

This phase II trial test tests how well repurposing atovaquone works in treating patients with platinum-resistant ovarian cancer. Atovaquone is used for the treatment or prevention of certain infections. Atovaquone is in a class of medications called antiprotozoal agents. It works by stopping the growth of certain types of protozoa that can cause pneumonia. Giving atovaquone may be effective in treating platinum-resistant ovarian cancer and result in improved outcomes compared to standard chemotherapy regimens.

Phase II Clinical Trial Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

Condition
Ovarian High Grade Serous Adenocarcinoma
Intervention / Treatment

-

Contacts and Locations

Atlanta

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States, 30322

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients with platinum-resistant, high-grade serous ovarian cancer, defined as disease progression within six months of completion of their last platinum-based chemotherapy
  • * Patients must maintain Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • * There will be no limitations on number of prior lines of therapy
  • * Trial is open to non-English speaking patients
  • * Trial is open to patients referred from community practice
  • * Patients who are \< 18 years old
  • * Patients who are pregnant or breastfeeding (due to cancer of their reproductive organs, patients enrolled in the trial are unable to conceive)
  • * Patients who are incarcerated
  • * Patients who are unable to provide consent / lack decision-making capacity

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Emory University,

Namita Khanna, MD, MSPH, PRINCIPAL_INVESTIGATOR, Emory University Hospital/Winship Cancer Institute

Study Record Dates

2026-06-30